- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00477100
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
Inflammatory Breast Cancer (IBC) Registry
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To prospectively collect tissue (including primary inflammatory breast cancer [IBC], ipsilateral nodal metastasis and/or distant metastasis [if applicable] obtained prior to primary systemic therapy and mastectomy/axillary dissection), serum, plasma, whole blood, clinical, and imaging data from patients with recently diagnosed inflammatory breast cancer (IBC), or highly suspicious for IBC, who have not received systemic therapy.
II. To collect paraffin tissue blocks or unstained slides (including primary, ipsilateral nodal metastasis and/or distant metastasis [if applicable] obtained prior to primary systemic therapy), mastectomy/axillary dissection tissue, serum, plasma, whole blood, clinical, and imaging data (if available) from patients with previously diagnosed inflammatory breast cancer (IBC), who have been treated or partially treated, but have not had mastectomy and are seeking further treatment in the IBC clinic at M. D. Anderson or participating cancer network sites.
III. To collect oral swab, skin and stool bacterial culture swab for microbiome analysis to compare patients with specific breast cancer subtype to report changes in flora during the course of treatment and correlated to toxicity.
OUTLINE:
Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jie Willey
- Phone Number: 713-792-3965
- Email: jwilley@mdanderson.org
Study Locations
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner - MD Anderson Cancer Center
-
Contact:
- Shakeela Bahadur, MD
- Phone Number: 480-256-6444
- Email: shakeela.bahadur@bannerhealth.com
-
Principal Investigator:
- Shakeela Bahadur, MD
-
-
California
-
La Jolla, California, United States, 92037
- Active, not recruiting
- Scripps - MD Anderson Cancer Center
-
-
Colorado
-
Greeley, Colorado, United States, 80631
- Recruiting
- Banner - MD Anderson Cancer Center - Northern Colorado
-
Contact:
- Esther Mondo, MD
- Phone Number: 970-820-5958
- Email: Esther.Mondo@BannerHealth.com
-
Principal Investigator:
- Esther Mondo, MD
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Recruiting
- Baptist - MD Anderson Cancer Center
-
Principal Investigator:
- Cynthia Anderson, MD
-
Contact:
- Cynthia Anderson, MD
- Phone Number: 904-202-7300
- Email: cynthia.anderson@bmcjax.com
-
-
Michigan
-
Saginaw, Michigan, United States, 48604
- Active, not recruiting
- Covenant Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Vicente Valero
- Phone Number: 713-563-0751
- Email: vvalero@mdanderson.org
-
Principal Investigator:
- Vicente Valero
-
Houston, Texas, United States, 77094
- Recruiting
- MD Anderson in Katy
-
Contact:
- Vicente Valero
- Phone Number: 713-563-0751
- Email: vvalero@mdanderson.org
-
Principal Investigator:
- Vicente Valero
-
Nassau Bay, Texas, United States, 77058
- Recruiting
- MD Anderson League City
-
Contact:
- Vicente Valero
- Phone Number: 713-563-0751
- Email: vvalero@mdanderson.org
-
Principal Investigator:
- Vicente Valero
-
Sugar Land, Texas, United States, 77478
- Recruiting
- MD Anderson in Sugar Land
-
Contact:
- Vicente Valero
- Phone Number: 713-560-0751
- Email: vvalero@mdanderson.org
-
Principal Investigator:
- Vicente Valero
-
The Woodlands, Texas, United States, 77384
- Recruiting
- MD Anderson in The Woodlands
-
Contact:
- Vicente Valero
- Phone Number: 713-563-0751
- Email: vvalero@mdanderson.org
-
Principal Investigator:
- Vicente Valero
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only).
- Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis.
- Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) [Cohort I] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only)
- Age > 18 years
- Able to provide informed consent
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (biospecimen and medical data collection)
Patients complete questionnaires and participate in interview over 30 minutes.
Patients also undergo collection of medical data and blood, tissue, and stool samples.
|
Participate in interview
Ancillary Studies
Undergo collection of blood, tissue, and stool
Undergo collection of medical data
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Data, serum, tissue, peripheral blood mononuclear cells, and plasma sample collection
Time Frame: Up to 2 years
|
No statistical considerations are provided.
For each clinical question that will use the data collected in this registry, a separate protocol will be submitted to the Institutional Review Board (IRB) that will include a sample size justification and an analysis plan.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: VIcente Valero, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-1072 (Other Identifier: M D Anderson Cancer Center)
- NCI-2018-01784 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Carcinoma
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Fondazione MichelangeloCompletedInvasive Ductal Breast CarcinomaSpain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
-
University of ChicagoActive, not recruitingLung Metastases | Liver Metastases | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Invasive Lobular Breast Carcinoma | Central Nervous System Metastases | Tumors Metastatic to Brain | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast... and other conditionsUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingInvasive Breast Cancer | Breast-conserving SurgeryFrance
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
St. Joseph Hospital of OrangeCompletedStage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast CarcinomaUnited States
Clinical Trials on Interview
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsCompleted
-
Ohio UniversityNew York Blood CenterCompleted
-
University of New MexicoCompletedPregnancy TerminationUnited States
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Centro Hospitalar Lisboa NorteUniversity of Lisbon; Faculdade de Psicologia e de Ciências de Educação da...Unknown
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, FranceCompletedCancer | Elderly | Ethnographic Interview | Social Representation of Being Aged | Reasons of Non-participation in Clinical Trials | Qualitative MethodFrance
-
Dongzhimen Hospital, BeijingUnknown
-
University of Eastern FinlandCompleted
-
University Hospital, GrenobleRegional Council of Auvergne-Rhône-AlpesRecruitingTraumatic Brain InjuryFrance
-
Northwestern UniversityRegeneron PharmaceuticalsCompletedPsoriasis | Atopic Dermatitis | IchthyosisUnited States